| Product Code: ETC10756581 | Publication Date: Apr 2025 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | No. of Pages: 65 | No. of Figures: 34 | No. of Tables: 19 | |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Greece PD-1 Non-Small Cell Lung Cancer Market Overview |
3.1 Greece Country Macro Economic Indicators |
3.2 Greece PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, 2021 & 2031F |
3.3 Greece PD-1 Non-Small Cell Lung Cancer Market - Industry Life Cycle |
3.4 Greece PD-1 Non-Small Cell Lung Cancer Market - Porter's Five Forces |
3.5 Greece PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume Share, By Drug Type, 2021 & 2031F |
3.6 Greece PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume Share, By Therapy Type, 2021 & 2031F |
3.7 Greece PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume Share, By Treatment Stage, 2021 & 2031F |
3.8 Greece PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume Share, By Mode of Action, 2021 & 2031F |
3.9 Greece PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume Share, By End User, 2021 & 2031F |
4 Greece PD-1 Non-Small Cell Lung Cancer Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of non-small cell lung cancer in Greece |
4.2.2 Growing awareness about PD-1 inhibitors for lung cancer treatment |
4.2.3 Rising investments in healthcare infrastructure and research development in Greece |
4.3 Market Restraints |
4.3.1 Stringent regulatory requirements for drug approval in Greece |
4.3.2 High cost associated with PD-1 inhibitors |
4.3.3 Limited access to advanced healthcare facilities in certain regions of Greece |
5 Greece PD-1 Non-Small Cell Lung Cancer Market Trends |
6 Greece PD-1 Non-Small Cell Lung Cancer Market, By Types |
6.1 Greece PD-1 Non-Small Cell Lung Cancer Market, By Drug Type |
6.1.1 Overview and Analysis |
6.1.2 Greece PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Drug Type, 2021 - 2031F |
6.1.3 Greece PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By PD-1 Inhibitors, 2021 - 2031F |
6.1.4 Greece PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By PD-L1 Inhibitors, 2021 - 2031F |
6.1.5 Greece PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Combination Therapy, 2021 - 2031F |
6.1.6 Greece PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Monotherapy, 2021 - 2031F |
6.1.7 Greece PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Adjuvant Therapy, 2021 - 2031F |
6.2 Greece PD-1 Non-Small Cell Lung Cancer Market, By Therapy Type |
6.2.1 Overview and Analysis |
6.2.2 Greece PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Immunotherapy, 2021 - 2031F |
6.2.3 Greece PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Chemotherapy, 2021 - 2031F |
6.2.4 Greece PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Radiation Therapy, 2021 - 2031F |
6.2.5 Greece PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Surgery, 2021 - 2031F |
6.2.6 Greece PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Palliative Care, 2021 - 2031F |
6.3 Greece PD-1 Non-Small Cell Lung Cancer Market, By Treatment Stage |
6.3.1 Overview and Analysis |
6.3.2 Greece PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By First-Line Treatment, 2021 - 2031F |
6.3.3 Greece PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Second-Line Treatment, 2021 - 2031F |
6.3.4 Greece PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Advanced-Stage Treatment, 2021 - 2031F |
6.3.5 Greece PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Recurrent Cancer Treatment, 2021 - 2031F |
6.3.6 Greece PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Metastatic Cancer Treatment, 2021 - 2031F |
6.4 Greece PD-1 Non-Small Cell Lung Cancer Market, By Mode of Action |
6.4.1 Overview and Analysis |
6.4.2 Greece PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Targeted Therapy, 2021 - 2031F |
6.4.3 Greece PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Checkpoint Inhibitors, 2021 - 2031F |
6.4.4 Greece PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Biomarker-Based Therapy, 2021 - 2031F |
6.4.5 Greece PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Immune Checkpoint Modulation, 2021 - 2031F |
6.4.6 Greece PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By T-Cell Activation, 2021 - 2031F |
6.5 Greece PD-1 Non-Small Cell Lung Cancer Market, By End User |
6.5.1 Overview and Analysis |
6.5.2 Greece PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Hospitals, 2021 - 2031F |
6.5.3 Greece PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Research Labs, 2021 - 2031F |
6.5.4 Greece PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Oncology Centers, 2021 - 2031F |
6.5.5 Greece PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Clinics, 2021 - 2031F |
6.5.6 Greece PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Diagnostic Centers, 2021 - 2031F |
7 Greece PD-1 Non-Small Cell Lung Cancer Market Import-Export Trade Statistics |
7.1 Greece PD-1 Non-Small Cell Lung Cancer Market Export to Major Countries |
7.2 Greece PD-1 Non-Small Cell Lung Cancer Market Imports from Major Countries |
8 Greece PD-1 Non-Small Cell Lung Cancer Market Key Performance Indicators |
8.1 Patient enrollment in clinical trials for PD-1 inhibitors |
8.2 Number of oncologists prescribing PD-1 inhibitors |
8.3 Adoption rate of PD-1 inhibitors in non-small cell lung cancer treatment |
9 Greece PD-1 Non-Small Cell Lung Cancer Market - Opportunity Assessment |
9.1 Greece PD-1 Non-Small Cell Lung Cancer Market Opportunity Assessment, By Drug Type, 2021 & 2031F |
9.2 Greece PD-1 Non-Small Cell Lung Cancer Market Opportunity Assessment, By Therapy Type, 2021 & 2031F |
9.3 Greece PD-1 Non-Small Cell Lung Cancer Market Opportunity Assessment, By Treatment Stage, 2021 & 2031F |
9.4 Greece PD-1 Non-Small Cell Lung Cancer Market Opportunity Assessment, By Mode of Action, 2021 & 2031F |
9.5 Greece PD-1 Non-Small Cell Lung Cancer Market Opportunity Assessment, By End User, 2021 & 2031F |
10 Greece PD-1 Non-Small Cell Lung Cancer Market - Competitive Landscape |
10.1 Greece PD-1 Non-Small Cell Lung Cancer Market Revenue Share, By Companies, 2024 |
10.2 Greece PD-1 Non-Small Cell Lung Cancer Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here